Q4 2024 Management View CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

BioMarin's highest-potential drug, Voxzogo, launched in late 2021. The drug has shown the ability to restore normal growth rates in young patients with achondroplasia, the most common form of ...

Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...

VOXZOGO for achondroplasia experienced 56% year-over-year growth, driven by global expansion and increased penetration in younger pediatric patients. Management also revealed plans to expand ...

Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $711.9 million. Product revenues totaled $735.6 million, which rose 16% year over year on higher ...

Total Revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions. In the quarter, revenues from BioMarin's Enzyme Therapies increased 9% ...